MX2017012775A - Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. - Google Patents

Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.

Info

Publication number
MX2017012775A
MX2017012775A MX2017012775A MX2017012775A MX2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A MX 2017012775 A MX2017012775 A MX 2017012775A
Authority
MX
Mexico
Prior art keywords
hig
antibody
luk
staphylococcus aureus
combination preparation
Prior art date
Application number
MX2017012775A
Other languages
English (en)
Inventor
Nagy Eszter
Rouha Harald
Stulik Lukas
Visram Zehra
Badarau Adriana
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of MX2017012775A publication Critical patent/MX2017012775A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una preparación combinatoria de anticuerpos anti-Staphylococcus aureus, que comprende a) un anticuerpo con neutralización cruzada de toxinas, que comprende por lo menos un sitio de unión poliespecífico que se une a toxina alfa (HIa) y por lo menos una de las toxinas de dos componentes seleccionadas de entre el grupo que consiste en HIgAB, HIgCB, LukSF, LukED, LukS-HlgB, LukSD, HIgA-LukD, HIgA-LukF, LukEF, LukE-HIgB, HlgC-LukD y HIgC-LukF; y b) un anticuerpo anti-LukGH; y/o c) un anticuerpo de OPK que reconoce una proteína de superficie de S. aureus, lo que en consecuencia induce OPK, específicamente un anticuerpo anti-proteína de unión a lg (IGBP) que comprende por lo menos un sitio de unión de CDR que reconoce a cualquiera de los dominios de unión a lgG de la Proteína A o Sbi de S. aureus.
MX2017012775A 2015-04-17 2016-04-14 Preparacion combinatoria de anticuerpos anti-staphylococcus aureus. MX2017012775A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15164000 2015-04-17
PCT/EP2016/058240 WO2016166223A1 (en) 2015-04-17 2016-04-14 Anti-staphylococcus aureus antibody combination preparation

Publications (1)

Publication Number Publication Date
MX2017012775A true MX2017012775A (es) 2019-04-29

Family

ID=52997891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012775A MX2017012775A (es) 2015-04-17 2016-04-14 Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.

Country Status (12)

Country Link
US (1) US20180179267A1 (es)
EP (1) EP3283514A1 (es)
JP (1) JP2018513168A (es)
KR (1) KR20170136637A (es)
CN (1) CN107873034A (es)
AU (1) AU2016249837A1 (es)
BR (1) BR112017021779A2 (es)
CA (1) CA2978855A1 (es)
IL (1) IL255062A0 (es)
MX (1) MX2017012775A (es)
RU (1) RU2017139800A (es)
WO (1) WO2016166223A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6694269B2 (ja) 2012-11-06 2020-05-13 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
BR112016008275A2 (pt) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
RU2017139800A (ru) * 2015-04-17 2019-05-17 Арсанис Байосайенсиз Гмбх Комбинированный препарат антител против staphylococcus aureus
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
TW202028232A (zh) 2018-10-09 2020-08-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
AU2019357983A1 (en) * 2018-10-09 2021-05-27 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
WO2008118476A2 (en) 2007-03-26 2008-10-02 Codon Devices, Inc. Cell surface display, screening and production of proteins of interest
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20110118447A1 (en) * 2007-12-31 2011-05-19 Xoma Technology Ltd. Methods and materials for targeted affinity enhancement
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
ES2812181T3 (es) * 2011-06-19 2021-03-16 Univ New York Métodos de tratamiento y prevención de infecciones por staphylococcus aureus y afecciones asociadas
BR112013032911A2 (pt) * 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida
CN103906535B (zh) * 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
CA2870223A1 (en) 2012-04-17 2013-10-24 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody
JP6694269B2 (ja) * 2012-11-06 2020-05-13 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
US20160074497A1 (en) 2013-05-03 2016-03-17 The University Of Chicago Staphylococcus live cell vaccines
RU2015154792A (ru) * 2013-05-21 2017-06-22 Арзанис Байэусайнсис ГмбХ Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus
BR112016008275A2 (pt) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
KR20160098358A (ko) * 2013-12-19 2016-08-18 알사니스 바이오사이언시스 게엠베하 스타필로코커스 아우레우스의 LukGH (LukAB) 독소에 대해 지시된 항체 및 항체 서열
CA2956429A1 (en) * 2014-08-12 2016-02-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
BR112017021830A2 (pt) * 2015-04-17 2018-07-10 Arsanis Biosciences Gmbh ?anticorpo monoclonal que neutraliza staphylococcus aureus, seu uso médico ou diagnóstico, uma preparação farmacêutica ou diagnóstica, moléculas de ácido nucleico que codificam o anticorpo e um método para produzir o anticorpo?
RU2017139800A (ru) * 2015-04-17 2019-05-17 Арсанис Байосайенсиз Гмбх Комбинированный препарат антител против staphylococcus aureus

Also Published As

Publication number Publication date
US20180179267A1 (en) 2018-06-28
WO2016166223A1 (en) 2016-10-20
RU2017139800A (ru) 2019-05-17
CN107873034A (zh) 2018-04-03
EP3283514A1 (en) 2018-02-21
JP2018513168A (ja) 2018-05-24
KR20170136637A (ko) 2017-12-11
IL255062A0 (en) 2017-12-31
AU2016249837A1 (en) 2017-09-28
BR112017021779A2 (pt) 2018-07-10
CA2978855A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
MX2017012775A (es) Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MD3443009T2 (ro) Anticorpi anti-TIM-3 și compoziții
CU20170169A7 (es) Anticuerpos de factor xi
PH12017500890A1 (en) Antibody drug conjugates
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
NZ757915A (en) Anti-par2 antibodies and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
MX2017001959A (es) Anticuerpos especificos para mmp9.
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
EA201990895A1 (ru) Антитела к о1 и варианты их применения
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2016007212A (es) Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
EA201590918A1 (ru) Антитела к bmp-6
EA201990222A1 (ru) Антитела к o2 и пути их применения